Perrigo Company PLC (PRGO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Perrigo Company PLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.10 $ — 5% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -1.5% failed
- More than 10% revenue growth is expected for the coming year 1.0% failed
- Share count grows by less than 3% a year 1.0% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.7% failed
- Gross margin at 40% or higher and without meaningful erosion 35.1% failed
- Goodwill from acquisitions does not grow faster than revenue 24.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 2,617 m passed
- Return on capital at 15% or higher, or up versus two years ago 4.6% passed
- Insiders hold at least 10% or are net buyers 0.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 63.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.11 | 2.07 – 2.15 | 4,063 | -23.3% | 5 |
| 12/31/2027 | 2.37 | 2.28 – 2.45 | 4,106 | 12.1% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.39 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.32 | – | 1,138 | -1.60 | -3.90 | 313 | 275 |
| 2025: Q1 | -0.05 | -419.80 | 1,044 | -3.50 | -0.60 | -65 | -90 |
| 2025: Q2 | -0.06 | – | 1,056 | -0.90 | -0.80 | 76 | 57 |
| 2025: Q3 | 0.05 | – | 1,043 | -4.10 | 0.70 | 52 | 30 |
| 2025: Q4 | -10.24 | – | 1,110 | -2.50 | -127.80 | 175 | 149 |
| 2026: Q1 | -2.87 | – | 969 | -7.20 | -41.10 | -114 | -127 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5,281 | -2,000 | -4,013 | -28.00 | 655 | 5,958 | 13,870 |
| 2017 | 4,946 | 598 | 120 | 0.84 | 699 | 6,171 | 11,629 |
| 2018 | 4,732 | 237 | 131 | 0.95 | 593 | 5,668 | 10,983 |
| 2019 | 3,870 | 175 | 146 | 1.07 | 388 | 5,804 | 11,301 |
| 2020 | 4,088 | 265 | -163 | -1.19 | 636 | 5,655 | 11,488 |
| 2021 | 4,139 | 410 | -69 | -0.52 | 156 | 5,152 | 10,426 |
| 2022 | 4,452 | 79 | -141 | -1.05 | 307 | 4,842 | 11,017 |
| 2023 | 4,656 | 152 | -13 | -0.09 | 406 | 4,768 | 10,809 |
| 2024 | 4,373 | 113 | -172 | -1.25 | 363 | 4,319 | 9,648 |
| 2025 | 4,253 | 343 | -1,425 | -10.29 | 239 | 2,936 | 8,535 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Perrigo Company plc bietet rezeptfreie Gesundheits- und Wellnesslösungen in den USA, Europa und international an. Das Unternehmen ist in den Segmenten Consumer Self-Care Americas und Consumer Self-Care International tätig.
| Employees | 8,100 |
|---|---|
| Headquarters | Dublin, Ireland |
| Address | The Sharp Building, D02 TY74 Dublin, Ireland |
| Phone | 353 1 709 4000 |
| Website | perrigo.com |
| IPO Date | 16. Dec 1991 |
| ISIN | IE00BGH1M568 |
| Stock Split | 2:1 on 08/26/1993 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Albert Ange Manzone | Interim President, Interim CEO & Director | 1963 |
| Eduardo Guarita Bezerra | Executive VP & CFO | 1976 |
| Abbie Lennox | EVP & Chief Scientific Officer | 1981 |
| Charles Atkinson | Executive VP, General Counsel & Secretary | 1977 |
| Roberto Khoury | Executive VP & Chief Commercial Officer | 1981 |
| Eric S. Jacobson | Vice President of Global Investor Relations | – |
| Robert Willis | Chief Human Resources Officer & Executive VP | 1969 |
| David Ball | EVP and Chief Brand & Digital Officer | 1980 |
| Matthew Winterman | Executive Vice President of Product Supply, Operations Strategy & Transformation Officer | 1971 |
| Sonia Hollies | Senior VP & Treasurer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8. Jul 2026 | Winterman Matthew John | EVP, Supply, Ops, Strategy | Other | 963 | 10.52 | 10,131 |
| 8. Jul 2026 | Winterman Matthew John | EVP, Supply, Ops, Strategy | Other | 1,843 | 10.52 | 19,388 |
| 8. Jul 2026 | Winterman Matthew John | EVP, Supply, Ops, Strategy | Other | 8,175 | 10.52 | 86,001 |
| 8. Jul 2026 | Winterman Matthew John | EVP, Supply, Ops, Strategy | Other | 15,660 | 10.52 | 164,743 |
| 8. Jul 2026 | Khoury Roberto | EVP and President of CSCI | Other | 385 | 10.52 | 4,050 |
| 8. Jul 2026 | Khoury Roberto | EVP and President of CSCI | Other | 737 | 10.52 | 7,753 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.